What About Offering a Financial Incentive Directly to Clinical Units to Encourage the Use of Biosimilars? Results of a Two-Year National Experiment in France.
Journal
Applied health economics and health policy
ISSN: 1179-1896
Titre abrégé: Appl Health Econ Health Policy
Pays: New Zealand
ID NLM: 101150314
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
accepted:
27
04
2023
medline:
7
8
2023
pubmed:
31
5
2023
entrez:
30
5
2023
Statut:
ppublish
Résumé
Regarding the low penetration of biosimilars in the French market, in 2018, the government introduced two mutually exclusive financial incentives to increase biosimilar use. They redirect 20% (general case) or 30% (experimental case) of the price difference between the reference product and its biosimilar to hospitals for every biosimilar delivered in retail pharmacies from these hospital prescriptions. The experimental case specifically targets prescribing clinical units. Our study aimed to assess whether the new payment scheme closer to physicians (experimental case) improved etanercept biosimilar penetration after 25 months. We evaluated hospital prescriptions using IQVIA Xponent data. The monthly number of etanercept boxes delivered in retail pharmacies was linked to the corresponding hospital prescription. The impact of the experimental case on the etanercept biosimilar rate was assessed by a difference-in-difference method. Among the 39 hospitals studied in the experimental case compared with the 169 belonging to the general case, a similar growing trend of etanercept biosimilar use was observed before October 2018. At the start of the experiment, there was an acceleration of biosimilar penetration in the experimental group, until both groups reached a plateau. A significant double difference estimator of 9.72 percentage points in favor of the experiment confirmed this (p < 2.2.10 The French experimental incentive appeared to be more effective at increasing biosimilar use. As it is expected to be implemented in all hospitals, the knowledge gained during this testing phase should allow adjustment of some of its terms and increase physician engagement.
Sections du résumé
BACKGROUND
Regarding the low penetration of biosimilars in the French market, in 2018, the government introduced two mutually exclusive financial incentives to increase biosimilar use. They redirect 20% (general case) or 30% (experimental case) of the price difference between the reference product and its biosimilar to hospitals for every biosimilar delivered in retail pharmacies from these hospital prescriptions. The experimental case specifically targets prescribing clinical units.
OBJECTIVES
Our study aimed to assess whether the new payment scheme closer to physicians (experimental case) improved etanercept biosimilar penetration after 25 months.
METHOD
We evaluated hospital prescriptions using IQVIA Xponent data. The monthly number of etanercept boxes delivered in retail pharmacies was linked to the corresponding hospital prescription. The impact of the experimental case on the etanercept biosimilar rate was assessed by a difference-in-difference method.
RESULTS
Among the 39 hospitals studied in the experimental case compared with the 169 belonging to the general case, a similar growing trend of etanercept biosimilar use was observed before October 2018. At the start of the experiment, there was an acceleration of biosimilar penetration in the experimental group, until both groups reached a plateau. A significant double difference estimator of 9.72 percentage points in favor of the experiment confirmed this (p < 2.2.10
CONCLUSION
The French experimental incentive appeared to be more effective at increasing biosimilar use. As it is expected to be implemented in all hospitals, the knowledge gained during this testing phase should allow adjustment of some of its terms and increase physician engagement.
Identifiants
pubmed: 37253898
doi: 10.1007/s40258-023-00812-w
pii: 10.1007/s40258-023-00812-w
pmc: PMC10228890
doi:
Substances chimiques
Etanercept
OP401G7OJC
Biosimilar Pharmaceuticals
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
799-811Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Global medicines use in 2020: outlook and implications. IMS Health for Healthcare Informatics Report, 2015. https://www.imshealth.com/en/thought-leadership/ims-institute/reports/global-medicines-use-in-2020#ims-form . Accessed 21 Feb 2016.
European Medicines Agency. Biosimilar medicines: Overview [Internet]. 2019 Oct. EMA/627319/2022. https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines-overview#regulatory-guidance-section . Accessed Oct 2022.
IQVIA. The Impact of Biosimilar Competition in Europe 2021. White paper online 2021, Dec. https://www.iqvia.com/library/white-papers/the-impact-of-biosimilar-competition-in-europe-2021 . Accessed Sept 2022.
Kim Y, Kwon HY, Godman B, Moorkens E, Simoens S, Bae S. Uptake of biosimilar infliximab in the UK, France, Japan, and Korea: budget savings or market expansion across countries? Front Pharmacol. 2020;11.
Rémuzat C, Dorey J, Cristeau O, Ionescu D, Radière G, Toumi M. Key drivers for market penetration of biosimilars in Europe. J Mark Access Health Policy. 2017;5(1):1272308.
doi: 10.1080/20016689.2016.1272308
pubmed: 28265349
pmcid: 5328350
IQVIA. Biosimilars reach inflection point – on track to reduce drug costs by $100 bn over next five years. 2020, Oct. https://www.iqvia.com/newsroom/2020/10/iqvia-institute-for-human-data-science-study-biosimilars-reach-inflection-point--on-track-to-reduce . Accessed Sept 2022.
Elyse Muñoz. A positive road ahead for biosimilars? IQVIA institute reports. 2021, Jan. https://www.iqvia.com/insights/the-iqvia-institute/reports/a-positive-road-ahead-for-biosimilars . Accessed Sept 2022.
IQVIA. Advancing biosimilar sustainability in Europe. 2018, Sept. IQVIA institute report. https://www.iqvia.com/insights/the-iqvia-institute/reports/advancing-biosimilar-sustainability-in-europe . Accessed Oct 2022.
IMS health. Delivering on the Potential of Biosimilar Medicines. 2016, March. https://www.medicinesforeurope.com/wp-content/uploads/2016/03/IMS-Institute-Biosimilar-Report-March-2016-FINAL.pdf . Accessed Oct 2022.
Moorkens E, Vulto AG, Huys I, Dylst P, Godman B, Keuerleber S, et al. Policies for biosimilar uptake in Europe: an overview. PLoS ONE. 2017;12(12): e0190147. https://doi.org/10.1371/journal.pone.0190147 .
doi: 10.1371/journal.pone.0190147
pubmed: 29284064
pmcid: 5746224
LOI n° 2013-1203 du 23 décembre 2013 de financement de la sécurité sociale pour 2014 [Internet]. JORF n°0298, NOR EFIX1324269L décembre, 2013. https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000028372809 . Accessed Sept 2022.
Ministère des solidarités et de la santé, ministère de l’Action et des comptes publics. INSTRUCTION N° DGOS/PF2/DSS/1C/DGS/PP2/2017/244 du 3 août 2017 relative aux médicaments biologiques, à leurs similaires ou « biosimilaires », et à l’interchangeabilité en cours des traitements - Légifrance [Internet]. NOR SSAH1722975J Dec 10, 2017. https://www.legifrance.gouv.fr/circulaire/id/42638 . Accessed Nov 2022.
IQVIA. The Impact of Biosimilar Competition in Europe 2022. White paper online 2022, Dec. https://www.iqvia.com/library/white-papers/the-impact-of-biosimilar-competition-in-europe-2022 . Accessed Mar 2022.
European Medicines Agency, European Commission. Biosimilars in the EU - Information guide for healthcare professionals [Internet]. European Medicines Agency; 2019 Feb p. 40. https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf . Accessed May 2022.
European Medicines Agency. Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU [Internet]. 2022 Sept. EMA/627319/2022. https://www.ema.europa.eu/en/documents/public-statement/statement-scientific-rationale-supporting-interchangeability-biosimilar-medicines-eu_en.pdf . Accessed Nov 2022.
Moorkens E, Simoens S, Troein P, Declerck P, Vulto AG, Huys I. Different policy measures and practices between swedish counties influence market dynamics: part 2—biosimilar and originator etanercept in the outpatient setting. BioDrugs. 2019;33(3):299–306.
doi: 10.1007/s40259-019-00346-5
pubmed: 30945206
pmcid: 6533216
Gibofsky A, McCabe D. US rheumatologists’ beliefs and knowledge about biosimilars: a survey. Rheumatol Oxf Engl. 2020;60(2):896–901.
doi: 10.1093/rheumatology/keaa502
Barcina Lacosta T, Vulto AG, Turcu-Stiolica A, Huys I, Simoens S. Qualitative analysis of the design and implementation of benefit-sharing programs for biologics across Europe. BioDrugs. 2022;36(2):217–29. https://doi.org/10.1007/s40259-022-00523-z . (Epub 2022 Mar 18).
doi: 10.1007/s40259-022-00523-z
pubmed: 35303281
pmcid: 8986662
INAMI (Belgian National Insurance Institute for Maladies and Invalidity) Prescrire « bon marché » [Internet] last update October 13, 2021. https://www.riziv.fgov.be/fr/professionnels/sante/medecins/soins/Pages/prescrire-bon-marche-20150101.aspx . Accessed Apr 2023.
Mathes T, Pieper D, Morche J, Polus S, Jaschinski T, Eikermann M. Pay for performance for hospitals. Cochrane Database Syst Rev. 2019;(7).
Seth W. Glickman MD, Eric D. Peterson MD. Innovative health reform models: pay-for-performance initiatives. Am J Manag Care. 2009.
Eijkenaar F. Pay for performance in health care: an international overview of initiatives. Med Care Res Rev. 2012;69(3):251–76.
doi: 10.1177/1077558711432891
pubmed: 22311954
Sécurité sociale. Les prescriptions hospitalières exécutées en ville [Internet]. Les Comptes de la sécurité sociale; 2020 Sep [cited 2022 Mar 2] p. 130–3. https://www.securite-sociale.fr/files/live/sites/SSFR/files/medias/CCSS/2020/FICHE_ECLAIRAGE/CCSS-FICHE_ECLAIRAGE-SEPT_2020-%20Les%20prescriptions%20hospitali%C3%A8res%20ex%C3%A9cut%C3%A9es%20en%20ville.pdf . Accessed Nov 2018.
Assurance Maladie. Rapport charges et produits, propositions de l’assurance maladie pour 2022.pdf [Internet]. 2021 juillet [cited 2022 Jun 10] pp. 65–77. https://assurance-maladie.ameli.fr/sites/default/files/rapport_charges_et_produits_-_propositions_de_lassurance_maladie_pour_2022_juillet_2021.pdf . Accessed June 2022.
Robinson JC, Jarrion Q. Competition from biosimilars drives price reductions for biologics in the French single-payer health system. Health Aff. 2021;40(8):1190–7.
doi: 10.1377/hlthaff.2021.00070
Ministère des solidarités et de la santé. Arrêté du 3 août 2018 relatif à l’expérimentation pour l’incitation à la prescription hospitalière de médicaments biologiques similaires délivrés en ville [Internet]. JORF n°0188, NOR SSAS1821431A août, 2018. https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000037316661 Accessed Sept 2020.
Lechat P. Médicaments biosimilaires: enjeux réglementaires et impacts médicoéconomiques. Bull Acad Natl Med. 2020;204(8):877–83.
pubmed: 32836292
pmcid: 7374147
Ministère des solidarités et de la santé. INSTRUCTION N° DSS/1C/DGOS/PF2/2018/42 du 19 février 2018 relative à l’incitation à la prescription hospitalière de médicaments biologiques similaires, lorsqu’ils sont délivrés en ville [Internet]. circulaire.legifrance.gouv.fr, NOR SSAS1805085J Feb 19, 2018. https://www.omedit-grand-est.ars.sante.fr/media/29966/download?inline . Accessed Sept 2020.
Ministère des solidarités et de la santé, ministère de l’Économie, des finances et de la relance. Arrêté du 2 octobre 2018 fixant la liste des établissements retenus dans le cadre de l’expérimentation pour l’incitation à la prescription hospitalière de médicaments biologiques similaires délivrés en ville [Internet]. JORF n°0233, NOR SSAS1826777A Oct 9, 2018. https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000037477126 . Accessed Sept 2022.
ATIH. Open data available from https://hospidiag.atih.sante.fr/ . Accessed May 2022.
Fougère D. Econometric evaluation methods. Rev Francaise Aff Soc. 2010;1:105–28.
Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41–55.
doi: 10.1093/biomet/70.1.41
Abadie A. Semiparametric difference-in-differences estimators. Rev Econ Stud. 2005;72:1–19. https://doi.org/10.2307/3700681 .
doi: 10.2307/3700681
Rubin DB. Matching to remove bias in observational studies. Biometrics. 1973;29:159–83.
doi: 10.2307/2529684
Ho DE, Imai K, King G, Stuart EA. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw. 2011;42(8):1–28. https://doi.org/10.18637/jss.v042.i08 .
doi: 10.18637/jss.v042.i08
Lemaire N. Avis du Comité technique de l’innovation en santé sur le projet d’expérimentation nationale « Incitation à la prescription hospitalière de médicaments biologiques similaires, lorsqu’ils sont délivrés en ville» [Internet]. 2022 Mar p. 2. https://solidarites-sante.gouv.fr/IMG/pdf/biosimilaires-avis_ctis-mars_2022.pdf . Accessed Apr 2022.
Daw JR, Hatfield LA. Matching and regression to the mean in difference-in-differences analysis. Health Serv Res. 2018;53(6):4138–56. https://doi.org/10.1111/1475-6773.12993 .
doi: 10.1111/1475-6773.12993
pubmed: 29957834
pmcid: 6232412
Rezk MF, Pieper B. To See or NOsee: the debate on the nocebo effect and optimizing the use of biosimilars. Adv Ther. 2018;35(6):749–53.
doi: 10.1007/s12325-018-0719-8
pubmed: 29873005
pmcid: 6096951
Scherlinger M, Langlois E, Germain V, Schaeverbeke T. Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4). Semin Arthritis Rheum. 2019;48(5):927–32.
doi: 10.1016/j.semarthrit.2018.07.005
pubmed: 30093238
Assurance Maladie. Rapport charges et produits-propositions de l’assurance maladie pour-2019.pdf [Internet]. 2018 Jul. https://assurance-maladie.ameli.fr/sites/default/files/2018-07_rapport-propositions-pour-2019_assurance-maladie.pdf . Accessed 10 June 2022.
Abbvie. AbbVie reports full-year and fourth-quarter 2018 financial results|AbbVie News Center [Internet]. 2019. https://news.abbvie.com/news/abbvie-reports-full-year-and-fourth-quarter-2018-financial-results.htm . Accessed 21 Feb 2022.